Page 25 - Gene Therapy Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

 E-Mail The AAVCOVID vaccine program, a novel gene-based vaccine strategy that utilizes an adeno-associated virus (AAV) vector, was granted an award for up to $2.1 million from the Bill & Melinda Gates Foundation. The grant will aid the effort to bring further preclinical validation to the AAV vaccine platform. An AAVCOVID vaccine candidate is set to enter clinical trials in 2021. The AAVCOVID vaccine program was founded at Mass General Brigham at the outset of the pandemic. Preliminary tests of the vaccines' stability and potency at different temperatures revealed that AAVCOVID candidat...

Passage Bio to Host First of a Series of 2021 Virtual R&D Events on January 25 PHILADELPHIA, Jan. 19, 2021 (GLOBE NEWSWIRE) — Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced it will host a series of virtual Research & Development events in 2021, with the first one scheduled for Monday, January 25, 2021, 11 a.m. to 1 p.m. ET. The first event will focus on Passage Bio’s lead investigational therapy PBGM01 and its disease target, infantile GM1 gangliosidosis (GM1...

Published: Jan 19, 2021 DALLAS--(BUSINESS WIRE)-- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system in both rare and large patient populations, today announced that it has received both rare pediatric disease and orphan drug designations from the U.S. Food and Drug Administration (FDA) for TSHA-105, an AAV9-based gene therapy in development for SLC13A5-related epilepsy. “There are no approved therapies for epilepsy caus...

Published: Dec 16, 2020 PHILADELPHIA, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system (CNS) disorders, today announced that it has entered into a long-term lease to support Chemistry, Manufacturing and Controls (CMC) laboratory operations for the company’s gene therapy programs. The new laboratory, slated to open in the second quarter of 2021 at the Princeton West Innovation Campus in Hopewell, New Jersey, will initially focus on state-of-the-art anal...

- MHRA approval represents first clinical trial authorization for the global PBGM01 clinical trial program - - Patient enrollment in UK clinical study site expected to start in the second quarter of 2021 -